28
Jul

KaloBios was an early entrant in 2013’s boom of biotech IPOs, touting its development technology as a springboard for high-quality antibodies. A year later, that promise hasn’t come to fruition, and partner Sanofi is walking away from an antibacterial program for which the company had high hopes.

…read more

Source: Sanofi dumps KaloBios’ antibiotic in another stinging setback

    

0 No comments